Titre :

Circulating vascular endothelial growth factor (vegf) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase ii trial of the french sarcoma group (gsf/geto)

Auteur(s) :

Lebellec, Loic [Auteur]
Université de Lille
Bertucci, François [Auteur]
Institut Paoli-Calmettes [IPC]
Tresch-Bruneel, Emmanuelle [Auteur]
Site de Recherche Intégrée en Cancérologie [SIRIC-ONCOLille]
Bompas, Emmanuelle [Auteur]
Centre René Gauducheau
Toiron, Yves [Auteur]
Institut Paoli-Calmettes [IPC]
Camoin, Luc [Auteur]
Institut Paoli-Calmettes [IPC]
Mir, Olivier [Auteur]
Institut Gustave Roussy [IGR]
Laurence, Valérie [Auteur]
Institut Curie [Paris]
Clisant-Delaine, Stephanie [Auteur]

Decoupigny, Emilie [Auteur]

Blay, Jean-Yves [Auteur]
Centre Léon Bérard [Lyon]
Goncalves, Anthony [Auteur]
Institut Paoli-Calmettes [IPC]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]

Titre de la revue :

Oncotarget

Nom court de la revue :

Oncotarget

Numéro :

7

Pagination :

73984-73994

Date de publication :

2016-11-08

ISSN :

1949-2553

Mot(s)-clé(s) en anglais :

biomarker
placental growth factor
sorafenib
chordoma
vascular endothelial growth factor
Mesh:Protein Kinase Inhibitors/therapeutic use
Mesh:Chordoma/drug therapy
Mesh:Chordoma/blood*
Mesh:Biomarkers
Mesh:Tumor
Mesh:Antineoplastic Agents/therapeutic use
Mesh:Aged
Mesh:80 and over
Mesh:Aged
Mesh:Neoplasm Staging
Mesh:Neoplasm Metastasis
Mesh:Middle Aged
Mesh:Membrane Proteins/blood
Mesh:Male
Mesh:Kaplan-Meier Estimate
Mesh:Humans
Mesh:Niacinamide/analogs & derivatives
Mesh:Female
Mesh:Combined Modality Therapy
Mesh:Clinical Trials
Mesh:Phase II as Topic
Mesh:Niacinamide/therapeutic use
Mesh:Phenylurea Compounds/therapeutic use
Mesh:Prognosis
Mesh:Adult
Mesh:Chordoma/pathology
Mesh:Chordoma/mortality*
Mesh:Vascular Endothelial Growth Factor A/blood*

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

BACKGROUND: Patients with advanced chordoma are often treated with tyrosine kinase inhibitors without any predictive factor to guide decision. We report herein an ancillary analysis of the the Angionext phase II trial (NCT ...
Lire la suite >BACKGROUND: Patients with advanced chordoma are often treated with tyrosine kinase inhibitors without any predictive factor to guide decision. We report herein an ancillary analysis of the the Angionext phase II trial (NCT 00874874). RESULTS: From May 2011 to January 2014, 26 were sampled. The 9-month PFS rate was 72.9% (95%-CI: 45.9-87.9). During sorafenib treatment, a significant increase in PlGF (18.4 vs 43.8 pg/mL, p<0.001) was noted along with a non-significant increase in VEGF (0.7 vs 1.0 ng/mL, p=0.07). VEGF at D1 >1.04 ng/mL (HR=12.5, 95%-CI: 1.37-114, p=0.025) and VEGF at D7 >1.36 ng/mL (HR=10.7, 95%-CI: 1.16-98, p=0.037) were associated with shorter PFS. The 9-month PFS rate was 92.3% (95%-CI: 56.6-98.9) when VEGF at D1 was ≤1.04 ng/mL versus 23.3% (95%-CI: 1.0-63.2) when >1.04 ng/mL. METHODS: Chordoma patients were treated with sorafenib 800 mg/day for 9 months, unless earlier occurrence of progression or toxicities. Six biomarkers (sE-Selectin, VEGF, VEGF-C, placental growth factor (PlGF), Thrombospondin, Stem Cell Factor (SCF)) were measured at baseline (day 1: D1) and day 7 (D7). CONCLUSIONS: High levels of VEGF was associated with poor outcome.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Université de Lille

Collections :

• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Date de dépôt :

2019-12-09T18:15:30Z
2020-05-28T08:13:12Z